Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953431 · ClinicalTrials.gov registry record · NA
Increased Lung Volume as Controller Therapy for Asthma
A NA study, sponsored by University of Vermont.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT02953431 is a NA study that has completed, run by University of Vermont. The registered enrollment target is 60 participants.
The verdict
NCT02953431, a NA study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an early phase clinical trial to test the efficacy of elevating lung volume with positive expiratory pressure (CPAP) as a controller therapy for asthma in patients with a BMI ≥ 30 kg/m2. There will be two phases to this trial. Phase I: In the first phase we will determine the optimal duration of CPAP that is effective as a controller therapy in asthma. Up to 9 participants will complete this this phase. Phase II: The 2nd phase will be a randomized double-blinded controlled trial of Sham CPAP versus CPAP 10 (using the duration of CPAP determined in phase I) as a controller therapy for asthma, and also to determine the effect o airway reactivity in healthy people with a BMI 30 kg/m2 and above. Twenty people with asthma and twenty controls will complete this phase.
Interventions
- DEVICE CPAP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2023-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953431
The ClinicalTrials.gov registry entry for NCT02953431 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CPAP is the first listed.
NCT02953431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02953431 about?
NCT02953431 is a clinical study titled "Increased Lung Volume as Controller Therapy for Asthma". This is an early phase clinical trial to test the efficacy of elevating lung volume with positive expiratory pressure (CPAP) as a controller therapy for asthma in patients with a BMI ≥ 30 kg/m2. There will be two phases to this trial. Phase I: In the first phase we will determine the optimal dura...
What is the current status of trial NCT02953431?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2018-05-07. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT02953431?
The interventions under investigation include: CPAP (DEVICE).
Who is sponsoring clinical trial NCT02953431?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.